To Describe the Use of Intravitreal Aflibercept and to Describe Follow-up as Well as Treatment Patterns in Patients With Wet Age-related Macular Degeneration (wAMD) or Diabetic Macular Edema (DME) in Routine Clinical Practice in Canada.

Sponsor
Bayer
Study ID
NCT02540369
Status
Completed

Conditions

  • Wet Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To describe the use of intravitreal aflibercept in routine clinical practice and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Canada for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc).

Key Dates

Start date
Dec 14, 2015
Status verified
Feb 2019
Primary completion
Sep 25, 2017
Completion
Jan 26, 2018

Study Design

Enrollment
2,150 participants (actual)

Arms

  • Arm: BAY86-5321- with wAMD
    Patients with wet Age Related Macular Degeneration (wAMD) both naïve and previously treated patients
  • Arm: BAY86-5321 - with DME
    Patients with Diabetic Macular Edema (DME) both naïve and previously treated patients

Primary Outcome Measure

Mean change of visual acuity. [ Time Frame: Baseline and 12 months ]

Related Studies